Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
Epizyme
What Does Epizyme Do?
Epizyme, Inc. was a clinical-stage biopharmaceutical company dedicated to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Their most notable achievement was the development and commercialization of TAZVERIK® (tazemetostat), an EZH2 inhibitor approved by the U.S. FDA for certain types of follicular lymphoma and epithelioid sarcoma. Founded in 2007, Epizyme focused on discovering, developing, and commercializing medicines that target the enzymes and proteins that regulate gene expression. In August 2022, Epizyme was acquired by Ipsen, a global biopharmaceutical group, in a move designed to bolster Ipsen's oncology portfolio and expand its U.S. presence. Epizyme's pioneering work in epigenetics continues within Ipsen's framework.
Where Is Epizyme's Headquarters?
HQ Function
Served as the primary hub for Epizyme's research, clinical development, commercial operations, and corporate administration before its integration into Ipsen.
Notable Features:
Located in the vibrant Kendall Square area, known for its high concentration of life science companies, research institutions like MIT, and venture capital firms, fostering a rich ecosystem for innovation.
Work Culture:
Epizyme was recognized for its innovative, science-driven, and patient-centric work culture. Employees were typically passionate about advancing epigenetic therapies and making a tangible difference in patients' lives, within a collaborative and dynamic environment.
HQ Significance:
The Cambridge headquarters was instrumental in Epizyme's journey from a research-focused startup to a commercial-stage biopharmaceutical company, including the successful development and launch of TAZVERIK®.
Values Reflected in HQ: The headquarters embodied Epizyme's commitment to scientific excellence, innovation in drug development, and a deep-seated focus on addressing unmet patient needs in oncology.
Location:
Before being acquired by Ipsen, Epizyme's primary operational and commercial focus was within the United States, centered around the development and launch of TAZVERIK®. Its global reach was mainly through clinical trial activities conducted in various countries. Post-acquisition, Epizyme's assets and programs are integrated into Ipsen's extensive global network, which spans North America, Europe, and other international markets, supporting research, development, and commercialization worldwide.
Street Address:
400 Technology Square
City:
Cambridge
State/Province:
Massachusetts
Country:
USA
Where Else Does Epizyme Operate Around the World?
No additional office locations available.
Buying Intent Signals for Epizyme
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Who's Leading Epizyme? Meet the Executive Team
As of April 2025, Epizyme' leadership includes:
Who's Investing in Epizyme?
Epizyme has been backed by several prominent investors over the years, including:
What Leadership Changes Has Epizyme Seen Recently?
Following Epizyme's acquisition by Ipsen, finalized in August 2022, the company's executive leadership team underwent a complete transition. Most former Epizyme executives departed, and the leadership of its assets and programs was integrated into Ipsen's structure. There have been no new executive hires for Epizyme as a standalone entity in the last 12 months, as it no longer operates independently.
Departures
What Technology (Tech Stack) Is Used byEpizyme?
Discover the tools Epizyme uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Epizyme Email Formats and Examples
Prior to its acquisition by Ipsen in August 2022, Epizyme, Inc. utilized standard corporate email formats. The most common format was likely [first_initial][last]@epizyme.com. Following the acquisition, the epizyme.com email domain is no longer actively used for ongoing company communications, which are now handled through Ipsen's systems.
[first_initial][last]@epizyme.com
Format
jdoe@epizyme.com
Example
0%
Success rate
What's the Latest News About Epizyme?
Ipsen Press Release • August 16, 2022
Ipsen completes acquisition of Epizyme
Ipsen announced the successful completion of its tender offer to acquire all outstanding shares of Epizyme, Inc. The acquisition strengthens Ipsen's Oncology portfolio with TAZVERIK® (tazemetostat) and Epizyme's pipeline....more
Epizyme Press Release • June 23, 2022
Ipsen to Acquire Epizyme, Further Strengthening its Oncology Portfolio
Epizyme announced that it had entered into a definitive merger agreement under which Ipsen would acquire Epizyme for $1.45 per share in cash at closing plus a contingent value right (CVR)....more
FDA.gov / Epizyme Press Release • June 18, 2020
Epizyme (now an Ipsen company) Announces FDA Accelerated Approval of TAZVERIK® (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to TAZVERIK® (tazemetostat) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options....more
FDA.gov / Epizyme Press Release • January 23, 2020
Epizyme (now an Ipsen company) Announces FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Metastatic or Locally Advanced Epithelioid Sarcoma
Epizyme announced that the U.S. Food and Drug Administration (FDA) granted Accelerated Approval for TAZVERIK™ (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) not eligible for complete resection....more
Highperformr's free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Epizyme, are just a search away.